BEDOUKIAN RESEARCH INC. PARTNERS WITH INSCRIPTA TO SUSTAINABLY DEVELOP AND MANUFACTURE NATURALLY PRODUCED INGREDIENTS
The partnership aims to deliver naturally produced products with superior quality and consistency, while reducing the environmental footprint associated with...
Read More
Inside the World of Genome Engineering at Amyris with Kirsten Benjamin, VP of R&D
Kirsten Benjamin of Amyris Takes Us into the World of Genome-Wide Engineering Amyris has long been the Bay Area’s crown...
Read More
Heterologous protein production in Yeast – New App Note
Protein production plays an important role in the growing bioeconomy industry. With various applications in biotechnology and biopharma — from…
Read More
Heterologous protein optimization in E. coli – New App Note
Heterologous protein expression underpins many advancements in modern molecular biology, including protein engineering, production of…
Read More
Writing in the Language of DNA: Kevin Ness on The Long Run
Kevin Ness, CEO of Inscripta, joins Luke Timmerman on this episode of the biotech podcast, The Long Run.
Read More
Amyris Partners with Inscripta® to Enhance Development of Sustainable Ingredients Using the Onyx® Genome Engineering Platform
Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company active in the Clean Health and Beauty markets through its consumer…
Read More
Population bottlenecks strongly affect the evolutionary dynamics of antibiotic persistence
Bacterial persistence is a potential cause of antibiotic therapy failure. Antibiotic-tolerant persisters originate from phenotypic…
Read More
The World’s First Fully Automated Benchtop Digital Genome Engineering Platform Is Here
As synthetic biology continues to grow, advanced benchtop systems are becoming available to make research and product development easier. Now,…
Read More
Inscripta® CEO on Genomic Engineering (Podcast)
Sri Kosaraju, Chief Executive Officer at Inscripta, discusses the far-reaching impact of the bio economy.
Read More
Inscripta® Eyes Broader Genome Editing Reach with $150M Series E
he Boulder, CO, gene editing biotech celebrates the inaugural installation of its Onyx platform in a British lab.
Read More